Abstract:Abstract Diffuse Midline Glioma (DMG) are fatal pediatric brain tumors with no therapies. We leveraged network-based methodologies to dissect the heterogeneity of DMG tumors and to discover Master Regulator (MR) proteins representing pharmacologically accessible, mechanistic determinants of molecularly distinct cell states. We produced the first DMG regulatory network from 122 publicly available RNAseq profiles with ARACNe (Basso et al. Nat Genet 2005), and inferred sample-specific MR protein activity with VIPER (Alvarez et al. Nat Genet 2016) based on the differential expression of their targets. 7 of the top 25 most active MRs found comprise a well-characterized MR block (MRB2) (Paull et al.Cell 2021), frequently activated across aggressive tumors, and enriched in DMG patient MR signatures (Fisher’s Exact Test p=4.4 × 10−18). A CRISPR/Cas9 KO screen across 3 DMG patient cell lines identified a set of 73/77 essential genes that were enriched in the MR signature of 80% of patient samples (GSEA p=0.000034). FOXM1 emerged as an essential MR, significantly activated across virtually all patients. We then generated RNAseq profiles following perturbation with ~300 oncology drugs in 2 DMG cell lines most representative of patient MR signatures, and used this to identify drugs that invert patient MR activity profiles using the NYS/CA Dept. of Health approved OncoTreat algorithm (Alvarez et al. Nat Genet 2018). OncoTreat predicted sensitivity to HDAC, MEK, CDK, PI3K, and proteosome inhibitors in subsets of patients, overlapping with published DMG drug screens. Importantly, 80% of OncoTreat-predicted drugs (p<10−5) from 3 DMG patient tumor biopsies showed in vitro sensitivity in cultured tumor cells from the respective patients, with overall 68% accuracy among 223 drugs evaluated by both OncoTreat and in vitro (Fisher’s Exact Test p=0.0449). Further analysis of DMG intra-tumor heterogeneity via protein activity inference across DMG single cells from 6 published scRNAseq profiles identified 6 tumor clusters with unique MR signatures co-existing in virtually all patients representing distinct cellular states (2 astrocyte-, 1 oligodendrocyte-, and 3 oligodendrocyte precursor cell-like states). Targetable MRs and OncoTreat-predicted drugs were distinct between these states. Bulk RNAseq analysis recapitulated predictions seen in the more prevalent OPC-like states, but failed to capture MR and drug predictions for the AC-like states (e.g. JAK1/Ruxolitinib and STAT3/Napabucasin). We are currently validating cell state-specific drug predictions in vivo at single-cell resolution in subcutaneous patient-derived xenograft and orthotopic syngeneic DMG models that we have shown recapitulate patient tumor heterogeneity, including with focused ultrasound-mediated drug delivery. This provides a platform to nominate much-needed novel drugs and drug combinations to treat DMG. Citation Format: Ester Calvo Fernandez, Junqiang Wang, Xu Zhang, Hong-Jian Wei, Hanna E. Minns, Aaron T. Griffin, Lukas Vlahos, Timothy J. Martins, Pamela S. Becker, John Crawford, Robyn D. Gartrell, Luca Szalontay, Stergios Zacharoulis, Zhiguo Zhang, Robert Wechsler-Reya, Cheng-Chia Wu, Andrea Califano, Jovana Pavisic. Network-based inference identifies cell state-specific drugs targeting master regulator vulnerabilities in diffuse midline glioma. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4304.

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

Cnsc-49. Elucidating Therapeutic Potential Of Usp1 Inhibition In Diffuse Midline Gliomas

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

Csig-13. Targeting Genetic Dependencies Exposes Diffuse Midline Glioma Cell Of Origin Vulnerabilities

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma

Convergent Evolution and Multi-Wave Clonal Invasion in H3 K27-altered Diffuse Midline Gliomas Treated with a PDGFR Inhibitor.

Abstract 4304: Network-based inference identifies cell state-specific drugs targeting master regulator vulnerabilities in diffuse midline glioma

Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence

DIPG-14. INTEGRATED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) NEXT-GENERATION SEQUENCING REVEALS EPIGENETIC DYSREGULATION OF GENE EXPRESSION AND BROMODOMAIN INHIBITION AS A NOVEL THERAPEUTIC TARGET

Pharmacologic Inhibition Of Lysine-Specific Demethylase 1 As A Therapeutic And Immune-Sensitization Strategy In Pediatric High-Grade Glioma

Immu-13. Trans-Species Study Of Idh-Mutant Replication-Repair Deficient High-Grade Gliomas (Rrd-Hgg) And Response To Combined Targeted And Immunotherapy: An Irrdc Study

Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges

TMOD-18. DIRECT IN VIVO CRISPR SCREEN IDENTIFIES COOPERATING TUMOR SUPPRESSORS THAT DRIVE PROGRESSION OF IDH1-MUTANT LOW-GRADE GLIOMA TO AGGRESSIVE GLIOBLASTOMA

DIPG-18. MULTIMODALITY VISUALIZATION OF A PRECLINICAL MODEL OF DIFFUSE MIDLINE GLIOMA DEMONSTRATES CLEAR TREATMENT EFFECT AFTER RNA NANOPARTICLE THERAPY

EXTH-67. PHARMACOLOGIC INHIBITION OF LYSINE SPECIFIC DEMETHYLASE-1 (LSD1) AS AN ADJUVANT IMMUNE-SENSITIZATION STRATEGY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time

DIPG-34. SUPER ELONGATION COMPLEX AS A TARGETABLE DEPENDENCY IN H3K27M+ DIFFUSE MIDLINE GLIOMA

PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma

DIPG-66. MULTIPLEXED IMMUNOFLUORESCENCE MAPPING AND AI MODEL PREDICTION OF TUMOR MICROENVIRONMENT IN DIFFUSE MIDLINE GLIOMAS

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy